Phase II trial of autophagy inhibition using hydroxychloroquine (HCQ) with FOLFOX/bevacizumab in the first-line treatment of advanced colorectal cancer

Authors :: Mark H. O'Hara
Irina A. Vasilevskaya
Peter J. O'Dwyer
Nevena Damjanov
Mark A. Rosen
Ravi K. Amaravadi
Ursina R. Teitelbaum
Arturo Loaiza-Bonilla
Daniel F. Heitjan
Maryann Redlinger
Source :: Journal of Clinical Oncology. 33:3614-3614
Publication Year :: 2015
Publisher :: American Society of Clinical Oncology (ASCO), 2015.
Abstract: 3614 Background: We have shown that autophagy, the regulated dissolution of cellular elements to maintain survival in adverse environmental conditions, is a determinant of resistance to chemotherap...

Subjects :: Oncology
Cancer Research
medicine.medical_specialty
Bevacizumab
business.industry
Autophagy
Hydroxychloroquine
Advanced colorectal cancer
First line treatment
FOLFOX
Internal medicine
medicine
business
medicine.drug
A determinant

Full Text Access

Tools